Characteristic | |
---|---|
Age median, years (IQR) | 45 (20–67) |
Males, n (%) | 15 (48.4) |
Fentanyl, μg; median (IQR) | 75 (50–100) |
Midazolam, mg; median (IQR) | 5 (4–10) |
Endoscopy purpose, n (%) | |
- Index | 10 (32.2) |
- Surveillance | 21 (67.8) |
CDH1 pathogenic variant status, n (%) | |
- Positive | 27 (87.1) |
- Variant of unknown significance | 1 (3.2) |
- Negative | 3 (9.7) |
Previous history of positive signet ring cell carcinoma finding n (%) | 15 (48.4) |
Ethnicity, n (%) | |
- White British | 14 (45.2) |
- Other white | 9 (29.2) |
- Asian | 8 (25.6) |
Number of pale areas assessed with pCLE per procedure, median (IQR) | 2 (1–5) |
Number of control areas assessed with pCLE per procedure, median (IQR) | 1 (1–2) |
Number of targeted biopsies taken, median (IQR) | 5 (2–11) |
Pale area location, n (%) | |
- pre-pyloric area | 1 (1.3) |
- antrum | 44 (57.1) |
- t-zone | 3 (3.9) |
- body | 8 (10.4) |
- fundus | 21 (27.3) |
Foci of signet ring cell locationa, n (%) | |
- pre-pyloric area | 0 (0) |
- antrum | 16 (72.8) |
- t-zone | 0 (0) |
- body | 4 (18.1) |
- fundus | 2 (9.1) |